rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

National Vision Holdings, Inc.

EYE · Nasdaq

Health CareMedical DevicesNot moving yet

EYE stood above a rising 150-day average in 21 of the last 52 weekly readings, and has been out of that trend for the last 30 weeks. It is 13.0% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 30
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$1.6M
Insider sales, 12 months
$2.5M
Officials’ trades on record
1
Institutions holding
218 (-19)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 21 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$3.2M$0$1.4MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Susie Lee House: U.S. House ClerkNV03sold$1k–$15k20 Mar 2019filed 8 Apr 2019

Insiders

Buy orders, 12 months1
Sale orders, 12 months2
Buyers · sellers1 · 2
WhoDidSharesTraded
Michael J. NicholsonDirectorbought50,000at $15.525 Jun 2026filed 9 Jun 2026
Alexander WilkesChief Executive Officersold35,000at $26.5411 Mar 2026filed 12 Mar 2026
L. Reade FahsExecutive Chairmansold7,601at $29.586 Mar 2026filed 9 Mar 2026
L. Reade FahsExecutive Chairmansold4,071at $29.576 Mar 2026filed 9 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders218-19 on the quarter
New · exited46 · 64
Reported value$1.9B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202612,114,392$230.3M+578,754+5.0%
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 20267,669,853$145.8M+2,173,887+39.6%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 20265,432,564$103.3M-314,419−5.5%
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCadded · filed 12 Aug 20264,747,422$90.2M+521,656+12.3%
FMR LLCadded · filed 13 Aug 20264,070,392$77.4M+2,979,948+273.3%
Engine Capital Management, LPadded · filed 14 Aug 20263,520,944$66.9M+3,511,406+36814.9%
STATE STREET CORPadded · filed 7 Aug 20263,465,157$65.9M+287,081+9.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20263,400,130$64.6M-37,737−1.1%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20263,384,805$64.3M+322,614+10.5%
AMERIPRISE FINANCIAL INCadded · filed 14 Aug 20263,148,704$59.9M+1,849,624+142.4%
31 Mar 2023 – 30 Jun 2026
152196239Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

David G. Cutler Company insiderChief Technology Officer · last 8 Sep 20260 · 0
Ana Moeddel Company insiderCHIEF MERCH. & MC OFFICER · last 2 Sep 20260 · 0
Alexander Wilkes Company insiderChief Executive Officer · last 19 Aug 20260 · 1
Mark Banner Company insiderPresident, America's Best · last 8 Jul 20260 · 0
Caitlin Zulla Company insiderDirector · last 17 Jun 20260 · 0
James M. McGrann Company insiderDirector · last 17 Jun 20260 · 0
Jose Armario Company insiderDirector · last 17 Jun 20260 · 0
Michael J. Nicholson Company insiderDirector · last 17 Jun 20261 · 0
Naomi Kelman Company insiderDirector · last 17 Jun 20260 · 0
Susan C. OFarrell Company insiderDirector · last 17 Jun 20260 · 0
Susan S. Johnson Company insiderDirector · last 17 Jun 20260 · 0
Virginia A. Hepner Company insiderDirector · last 17 Jun 20262 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 3 Jan 20263.0%
Free cash flow marginFY 2025 · to 3 Jan 20263.7%
Return on capital employedFY 2025 · to 3 Jan 20263.7%
Cash conversionFY 2025 · to 3 Jan 2026494%
Debt to equityFY 2025 · to 3 Jan 20260.29×
Share count trendFY 2025 · to 20 Feb 20260.0%
Cash and equivalentsFY 2025 · to 3 Jan 2026$38.7M
Free cash flowFY 2025 · to 3 Jan 2026$73.5M

Analyst forecasts

No analyst forecasts yet.